Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that on December 31, 2022 it entered into a new long-term global supply agreement with Catalent for the manufacture of INBRIJA (levodopa inhalation powder) at its
December 22, 9:04 AM
Key Assumptions Underlying Business Plan and Guidance Remain Unchanged INBRIJA will continue to grow in the U.S. INBRIJA will expand into additional ex-U.S. markets AMPYRA will continue to lose market
December 20, 6:30 PM
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the Company's common stock not having regained compliance
Acorda Therapeutics Announces Passage Of ~2.5:1 Reverse Stock Split Proposal At Special Meeting of Stockholders
November 11, 10:56 AM
"We are grateful to our shareholders who supported this proposal at a ratio of almost two and a half to one. Authorizing our board to implement a reverse stock split is an important tool, if needed, to ensure that
November 9, 4:06 PM
Acorda Therapeutics's (NASDAQ:ACOR) short percent of float has risen 230.3% since its last report. The company recently reported that it has 792 thousand shares sold short, which is 3.27% of all regular shares that are available for trading.
November 1, 2:10 PM
November 1, 3:31 AM
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.
October 31, 2:00 PM
October 28, 4:57 AM
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also reported better-than-expected Q3 sales results.
October 27, 1:33 PM